+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06728189

Phase 1 Study of CD70-targeted CAR-NKT Cell Therapy CGC738 for Adults with Advanced Malignant Solid Tumors

Led by Peking University Cancer Hospital & Institute · Updated on 2024-12-11

13

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, and pharmacokinetics of CGC738, a CD70-targeted CAR-NKT cell therapy, in adults with advanced malignant solid tumors that are CD70-positive. This phase I, open-label, single-arm study aims to determine the maximum tolerated dose and observe the treatments anti-tumor activity in patients who have recurrent or metastatic tumors after at least second-line treatment. The study includes two stages dose escalation and dose expansion. During dose escalation, three dose levels of CGC738 are tested using a rapid titration combined with a 33 design to assess dose-limiting toxicities within 28 days after infusion. Patients receive a lymphodepleting regimen with cyclophosphamide and fludarabine before infusion of CAR-NKT cells. Dose escalation stops once a safe dose with acceptable activity is identified. The dose expansion stage enrolls an additional group of patients to further evaluate safety and efficacy at the selected dose. Participants undergo leukapheresis for cell collection followed by lymphodepletion with cyclophosphamide and fludarabine before receiving CGC738 infusion. Researchers assess dose-limiting toxicities at day 28 and monitor objective response rate, disease control rate, adverse events, and CAR-NKT cell dynamics for up to 56 weeks. Participants are closely monitored for safety and efficacy during the study treatment period, which includes regular clinical evaluations and laboratory tests.

CONDITIONS

Brief Title

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors

Research Team

X

Xinan Sheng Professor, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here